Analyst Price Targets — VRCA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 18, 2025 8:41 am | Kemp Dolliver | Loop Capital Markets | $17.00 | $8.05 | StreetInsider | Brookline Capital Markets Upgrades Verrica Pharmaceuticals (VRCA) to Buy |
| May 14, 2024 9:35 am | Glen Santangelo | Jefferies | $12.00 | $11.28 | StreetInsider | Verrica Pharmaceuticals (VRCA) PT Raised to $12 at Jefferies |
| May 14, 2024 6:51 am | Oren Livnat | H.C. Wainwright | $14.00 | $9.56 | StreetInsider | Verrica Pharmaceuticals (VRCA) PT Raised to $14 at H.C. Wainwright |
| July 25, 2023 1:03 pm | Serge Belanger | Needham | $10.00 | $5.32 | Benzinga | Verrica's Ycanth Unlikely to Face Near-Term Competition, Analyst Upgrades Stock On FDA Approval |
Latest News for VRCA
WEST CHESTER, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced acceptance of a late-breaking abstract reporting Phase 2 exploratory data of VP-315, Verrica's novel oncolytic peptide for the treatment of basal cell…
WEST CHESTER, Pa., April 06, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the 25th Annual Needham Virtual Healthcare…
Vivani Medical (NASDAQ: VANI - Get Free Report) and Verrica Pharmaceuticals (NASDAQ: VRCA - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations. Profitability This table compares Vivani Medical and
LOS ANGELES--(BUSINESS WIRE)---- $VRCA--VRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law Firm.
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA). If you currently own shares of Verrica Pharmaceuticals stock, please visit the firm's website at https://rosenlegal.com/submit-form/?case_id=6828 for more information. You may also contact…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VRCA.
U.S. House Trading
No House trades found for VRCA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.